New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:34 EDTINSMInsmed EU update to provide near-term floor, says Piper Jaffray
Piper Jaffray attributes today's pullback in shares of Insmed to the company not immediately filing for U.S. approval of Arikayce in cystic fibrosis and nontuberculous mycobacteria. However, Piper believes the earlier than expected European filing will provide a near-term floor for shares. The firm also says the Phase 2 improvement in 6MWD in the Arikayce arm should "put to rest much of the debate over the drug's clinical utility." Piper reiterates an Overweight rating on Insmed with a $51 price target.
News For INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:07 EDTINSMInsmed provides end of year regulatory and clinical update
Subscribe for More Information
December 11, 2014
09:17 EDTINSMInsmed management to meet with Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use